BioCentury | Nov 18, 2020
Emerging Company Profile

Led by ElevateBio’s Finer, LifeEDIT is pursuing novel enzymes for gene editing

...portfolio companies —AlloVir Inc. (NASDAQ:ALVR) and HighPassBio...
BioCentury | Mar 30, 2020
Finance

ElevateBio raises $170M, plans additions to portfolio with six clinical programs by 2021

...subsidiary. ElevateBio has disclosed relationships with two -- antiviral play AlloVir and blood cancer company HighPassBio...
...develop a T cell therapy for immunocompromised patients who are at risk of developing COVID-19. HighPassBio...
...to treat and prevent relapse after hematopoietic stem cell transplant (HSCT) in leukemia patients (see “HighPassBio...
BioCentury | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

...HighPassBio and antiviral play AlloVir have since emerged as ElevateBio portfolio companies (see "ElevateBio Launches HighPassBio"...
BioCentury | Oct 1, 2019
Company News

ElevateBio launches HighPassBio with TCR immunotherapy focus

...Less than five months after its launch, ElevateBio has announced a second portfolio company: HighPassBio, which...
...is developing T cell immunotherapies based on research from the Fred Hutchinson Cancer Research Center. HighPassBio’s...
...to ClinicalTrials.gov, the trial is expected to enroll 24 patients and complete in October 2020. HighPassBio...
Items per page:
1 - 4 of 4
BioCentury | Nov 18, 2020
Emerging Company Profile

Led by ElevateBio’s Finer, LifeEDIT is pursuing novel enzymes for gene editing

...portfolio companies —AlloVir Inc. (NASDAQ:ALVR) and HighPassBio...
BioCentury | Mar 30, 2020
Finance

ElevateBio raises $170M, plans additions to portfolio with six clinical programs by 2021

...subsidiary. ElevateBio has disclosed relationships with two -- antiviral play AlloVir and blood cancer company HighPassBio...
...develop a T cell therapy for immunocompromised patients who are at risk of developing COVID-19. HighPassBio...
...to treat and prevent relapse after hematopoietic stem cell transplant (HSCT) in leukemia patients (see “HighPassBio...
BioCentury | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

...HighPassBio and antiviral play AlloVir have since emerged as ElevateBio portfolio companies (see "ElevateBio Launches HighPassBio"...
BioCentury | Oct 1, 2019
Company News

ElevateBio launches HighPassBio with TCR immunotherapy focus

...Less than five months after its launch, ElevateBio has announced a second portfolio company: HighPassBio, which...
...is developing T cell immunotherapies based on research from the Fred Hutchinson Cancer Research Center. HighPassBio’s...
...to ClinicalTrials.gov, the trial is expected to enroll 24 patients and complete in October 2020. HighPassBio...
Items per page:
1 - 4 of 4